Question 1

What was the main finding?

Accepted Answer

Myosteatosis (fatty muscle tissue) is a strong independent predictor of poor outcomes in advanced prostate cancer patients treated with enzalutamide, reducing failure-free survival from 17 months to just 6 months.

Question 2

Did sarcopenia (muscle loss) affect outcomes?

Accepted Answer

No, unlike myosteatosis, sarcopenia was not significantly associated with shorter failure-free survival in this study.

Question 3

How was muscle health measured?

Accepted Answer

Researchers used standard pretreatment abdominal CT scans to evaluate muscle quality and fat infiltration.

Does Muscle Fat (Myosteatosis) Predict Enzalutamide Success in Advanced Prostate Cancer?